Liposomal chemotherapeutics

Emanuela Gentile; Felisa Cilurzo; Luisa Di Marzio; Maria Carafa; Cinzia Anna Ventura; Joy Wolfram; Donatella Paolino; Christian Celia

doi:10.2217/fon.13.146

Liposomal chemotherapeutics

Emanuela Gentile, Felisa Cilurzo, Luisa Di Marzio, Maria Carafa, Cinzia Anna Ventura, Joy Wolfram, Donatella Paolino, Christian Celia

Houston Methodist

Research output: Contribution to journal › Article › peer-review

65 Scopus citations

Abstract

Currently, six liposomal chemotherapeutics have received clinical approval and many more are in clinical trials or undergoing preclinical evaluation. Liposomes exhibit low toxicity and improve the biopharmaceutical features and therapeutic index of drugs, thereby increasing efficacy and reducing side effects. In this review we discuss the advantages of using liposomes for the delivery of chemotherapeutics. Gemcitabine and paclitaxel have been chosen as examples to illustrate how the performance of a metabolically unstable or poorly water-soluble drug can be greatly improved by liposomal incorporation. We look at the beneficial effects of liposomes in a variety of solid and blood-borne tumors, including thyroid cancer, pancreatic cancer, breast cancer and multiple myeloma.

Original language	English (US)
Pages (from-to)	1849-59
Number of pages	11
Journal	Future Oncology
Volume	9
Issue number	12
DOIs	https://doi.org/10.2217/fon.13.146
State	Published - Dec 2013

Keywords

Breast Neoplasms
Deoxycytidine
Doxorubicin
Drug Delivery Systems
Female
Humans
Liposomes
Multiple Myeloma
Paclitaxel
Pancreatic Neoplasms
Thyroid Neoplasms
Journal Article
Review

Access to Document

10.2217/fon.13.146

Cite this

@article{e1a7827d3eb24b4fa904f86b27ab7a4e,

title = "Liposomal chemotherapeutics",

abstract = "Currently, six liposomal chemotherapeutics have received clinical approval and many more are in clinical trials or undergoing preclinical evaluation. Liposomes exhibit low toxicity and improve the biopharmaceutical features and therapeutic index of drugs, thereby increasing efficacy and reducing side effects. In this review we discuss the advantages of using liposomes for the delivery of chemotherapeutics. Gemcitabine and paclitaxel have been chosen as examples to illustrate how the performance of a metabolically unstable or poorly water-soluble drug can be greatly improved by liposomal incorporation. We look at the beneficial effects of liposomes in a variety of solid and blood-borne tumors, including thyroid cancer, pancreatic cancer, breast cancer and multiple myeloma.",

keywords = "Breast Neoplasms, Deoxycytidine, Doxorubicin, Drug Delivery Systems, Female, Humans, Liposomes, Multiple Myeloma, Paclitaxel, Pancreatic Neoplasms, Thyroid Neoplasms, Journal Article, Review",

author = "Emanuela Gentile and Felisa Cilurzo and {Di Marzio}, Luisa and Maria Carafa and Ventura, {Cinzia Anna} and Joy Wolfram and Donatella Paolino and Christian Celia",

year = "2013",

month = dec,

doi = "10.2217/fon.13.146",

language = "English (US)",

volume = "9",

pages = "1849--59",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "12",

}

TY - JOUR

T1 - Liposomal chemotherapeutics

AU - Gentile, Emanuela

AU - Cilurzo, Felisa

AU - Di Marzio, Luisa

AU - Carafa, Maria

AU - Ventura, Cinzia Anna

AU - Wolfram, Joy

AU - Paolino, Donatella

AU - Celia, Christian

PY - 2013/12

Y1 - 2013/12

N2 - Currently, six liposomal chemotherapeutics have received clinical approval and many more are in clinical trials or undergoing preclinical evaluation. Liposomes exhibit low toxicity and improve the biopharmaceutical features and therapeutic index of drugs, thereby increasing efficacy and reducing side effects. In this review we discuss the advantages of using liposomes for the delivery of chemotherapeutics. Gemcitabine and paclitaxel have been chosen as examples to illustrate how the performance of a metabolically unstable or poorly water-soluble drug can be greatly improved by liposomal incorporation. We look at the beneficial effects of liposomes in a variety of solid and blood-borne tumors, including thyroid cancer, pancreatic cancer, breast cancer and multiple myeloma.

AB - Currently, six liposomal chemotherapeutics have received clinical approval and many more are in clinical trials or undergoing preclinical evaluation. Liposomes exhibit low toxicity and improve the biopharmaceutical features and therapeutic index of drugs, thereby increasing efficacy and reducing side effects. In this review we discuss the advantages of using liposomes for the delivery of chemotherapeutics. Gemcitabine and paclitaxel have been chosen as examples to illustrate how the performance of a metabolically unstable or poorly water-soluble drug can be greatly improved by liposomal incorporation. We look at the beneficial effects of liposomes in a variety of solid and blood-borne tumors, including thyroid cancer, pancreatic cancer, breast cancer and multiple myeloma.

KW - Breast Neoplasms

KW - Deoxycytidine

KW - Doxorubicin

KW - Drug Delivery Systems

KW - Female

KW - Humans

KW - Liposomes

KW - Multiple Myeloma

KW - Paclitaxel

KW - Pancreatic Neoplasms

KW - Thyroid Neoplasms

KW - Journal Article

KW - Review

U2 - 10.2217/fon.13.146

DO - 10.2217/fon.13.146

M3 - Article

C2 - 24295415

SN - 1479-6694

VL - 9

SP - 1849

EP - 1859

JO - Future Oncology

JF - Future Oncology

IS - 12

ER -

Liposomal chemotherapeutics

Abstract

Keywords

Access to Document

Fingerprint

Cite this